Key Highlights
- Shares of Theriva Biologics (TOVX) stock rallied 63% following the release of updated VIRAGE Phase 2b clinical trial data
- Combination therapy of VCN-01 with standard chemotherapy demonstrated enhanced overall survival compared to chemotherapy alone in patients with metastatic pancreatic cancer
- Positive outcomes were observed across multiple patient subgroups, including those with liver metastases
- The company has secured regulatory alignment with both FDA and EMA for a planned Phase 3 pivotal study
- Theriva currently holds a market capitalization of approximately $11.7M with shares trading at $0.25, highlighting its early-stage clinical development status
Theriva Biologics unveiled updated findings from its VIRAGE Phase 2b clinical study during the American Association for Cancer Research (AACR) Annual Meeting held in San Diego on April 20, 2026.
Dr. Manuel Hidalgo from NYU Langone Health’s Perlmutter Cancer Center presented the data during a dedicated poster session.
The clinical study evaluated VCN-01 administered alongside gemcitabine and nab-paclitaxel versus standard chemotherapy alone in newly diagnosed metastatic pancreatic cancer patients.
Findings demonstrated that subjects receiving the VCN-01 combination therapy experienced superior overall survival and progression-free survival metrics compared to the control arm receiving only chemotherapy.
The therapeutic responses observed in the VCN-01 treatment arm were characterized as emerging later, demonstrating greater magnitude, and showing enhanced durability — suggesting what researchers believe indicates an immune-mediated therapeutic mechanism.
The survival advantages remained relatively consistent across various patient demographics. This included patients presenting with liver metastases, a population traditionally associated with more challenging treatment outcomes.
Subjects who received a second administration of VCN-01 demonstrated even more pronounced clinical benefits, which Theriva interprets as supporting evidence for extended dosing regimens.
Regulatory Pathway: Phase 3 Trial Design Approved
Theriva announced it has achieved regulatory alignment with both the U.S. Food and Drug Administration and the European Medicines Agency regarding the structure of a pivotal Phase 3 clinical trial.
The planned Phase 3 study will assess multiple doses of VCN-01 combined with gemcitabine and nab-paclitaxel in first-line treatment of metastatic pancreatic cancer patients.
Additionally, the company intends to conduct a smaller exploratory study investigating whether increased frequency or extended duration of VCN-01 administration could further enhance patient outcomes.
VCN-01 represents a systemically delivered oncolytic adenovirus designed to selectively replicate within tumor cells while degrading tumor stromal tissue, potentially enhancing therapeutic access for co-administered treatments.
To this point, the investigational therapy has been administered to 142 patients across multiple clinical trials spanning various cancer indications.
Market Response and Corporate Overview
TOVX stock experienced a 63% surge following the announcement, although the company maintains a modest market capitalization of just $11.7 million with shares priced at $0.25.
This valuation underscores the inherent risks associated with an early-stage biotechnology company operating without revenue generation and facing continued capital expenditure.
Wall Street Perspective
The latest analyst consensus rating for TOVX stands at Buy, featuring a price target of $1.00. Analyst price projections span a range from $1 to $4.
A notable operational challenge: Theriva recently failed to achieve quorum for a Special Meeting of Stockholders intended to approve a warrant exercise proposal. Management plans to reschedule this meeting.
Pancreatic ductal adenocarcinoma accounts for over 90% of all pancreatic malignancies, with approximately 50–60% of patients presenting with distant metastatic disease at initial diagnosis.
The AACR data presentation occurred on April 20 between 2:00–5:00 PM PDT at the San Diego Convention Center.
